Zydus to seek emergency nod for Covid vaccine soon

Ahmedabad-based Zydus Cadila is likely to seek emergency use authorisation for its Covid-19 vaccine candidate in the next 10-12 days, people familiar with the development told ET.

The company is expected to present phase III data for ZyCoV-D--a plasmid DNA vaccine—to the country’s drug regulatory authority by next week, the people cited earlier said.

Phase III trial for ZyCoV-D has been completed across 60 locations they said, adding that phase I and II trials were completed in January.


A senior government official said, “Phase III trials have been completed and it has been tested in 30,000 healthy adult volunteers in India.”

Zydus Cadila aims to supply 100-150 million doses of ZyCoV-D this calendar year. “This is likely to be expanded,” the people cited earlier said.

Phase II trial for ZyCoV-D was conducted on 1,000 participants.

The people cited earlier said data from phase II trial was reviewed by an independent Data Safety Monitoring Board (DSMB) and the vaccine candidate has been found to be safe and elicits a strong immunogenic response.